Atomoxetine increases fronto-parietal functional MRI activation in attention-deficit/hyperactivity disorder: a pilot study
Department of Quantitative Health Sciences
Behavioral Disciplines and Activities | Bioimaging and Biomedical Optics | Pharmacy and Pharmaceutical Sciences | Psychiatry and Psychology | Therapeutics
We hypothesized that atomoxetine (ATMX) would produce similar brain effects in attention-deficit/hyperactivity disorder (ADHD) as those of methylphenidate (MPH). Eleven ADHD adults performed the Multi-Source Interference Task (MSIT) during functional magnetic resonance imaging (fMRI) at baseline and after 6 weeks of ATMX treatment. ATMX was associated with increased fMRI activation of dorsolateral prefrontal cortex, parietal cortex and cerebellum but not dorsal anterior midcingulate cortex (daMCC). These results suggest that ATMX and MPH have similar but not identical brain effects.
Rights and Permissions
Citation: Epub 2012 Nov 10. Link to article on publisher's site
Bush, George; Holmes, Jennifer; Shin, Lisa M.; Surman, Craig; Makris, Nikos; Mick, Eric; Seidman, Larry J.; and Biederman, Joseph, "Atomoxetine increases fronto-parietal functional MRI activation in attention-deficit/hyperactivity disorder: a pilot study" (2012). Quantitative Health Sciences Publications and Presentations. 1105.